GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (STU:SMZ1) » Definitions » EV-to-EBITDA

Sino Biopharmaceutical (STU:SMZ1) EV-to-EBITDA : 8.23 (As of May. 03, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sino Biopharmaceutical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sino Biopharmaceutical's enterprise value is €6,257 Mil. Sino Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €760 Mil. Therefore, Sino Biopharmaceutical's EV-to-EBITDA for today is 8.23.

The historical rank and industry rank for Sino Biopharmaceutical's EV-to-EBITDA or its related term are showing as below:

STU:SMZ1' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.11   Med: 11.53   Max: 25.6
Current: 8.13

During the past 13 years, the highest EV-to-EBITDA of Sino Biopharmaceutical was 25.60. The lowest was 3.11. And the median was 11.53.

STU:SMZ1's EV-to-EBITDA is ranked better than
51.72% of 466 companies
in the Biotechnology industry
Industry Median: 9.15 vs STU:SMZ1: 8.13

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-03), Sino Biopharmaceutical's stock price is €0.3325. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.016. Therefore, Sino Biopharmaceutical's PE Ratio for today is 20.78.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Sino Biopharmaceutical EV-to-EBITDA Historical Data

The historical data trend for Sino Biopharmaceutical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical EV-to-EBITDA Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.09 17.68 4.42 12.29 9.43

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.42 - 12.29 - 9.43

Competitive Comparison of Sino Biopharmaceutical's EV-to-EBITDA

For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's EV-to-EBITDA falls into.



Sino Biopharmaceutical EV-to-EBITDA Calculation

Sino Biopharmaceutical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6257.171/759.999
=8.23

Sino Biopharmaceutical's current Enterprise Value is €6,257 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €760 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (STU:SMZ1) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Sino Biopharmaceutical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.3325/0.016
=20.78

Sino Biopharmaceutical's share price for today is €0.3325.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.016.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Sino Biopharmaceutical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (STU:SMZ1) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (STU:SMZ1) Headlines

No Headlines